

Commissioner for Patents
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Prior to examination, please amend the application as follows:

In the specification:

Please replace the paragraph beginning at page 1, line 6 with the following rewritten paragraph:

-- This application is a divisional (and claims the benefit of priority under 35 USC 120) of U.S. Application Serial No. 09/054,218, filed April 2, 1998, which claims priority from U.S. Provisional Application Serial No. 60/042,678, filed April 2, 1997. The disclosure of the prior application is considered part of (and is incorporated by reference in) the disclosure of this application. --

In the claims:

Please cancel claims 12-21, 23-27, and 29-39.

Please amend claim 22 as follows:

22. (Amended) A pharmaceutical composition comprising the polypeptide of claim 1.

CERTIFICATE OF MAILING BY EXPRESS MAIL

Express Mail Label No. EL298425360US

I hereby certify under 37 CFR §1.10 that this correspondence is being deposited with the United States Postal Service as Express Mail Post Office to Addressee with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

Date of Deposit June 4, 2001

Date of Deposit 10/10/2015
Signature [Signature]

Lisa G. Gray

Typed or Printed Name of Person Signing Certificate

Applicant : JENS CHR. JENSENIUS et al.
Serial No. :
Filed : June 4, 2001
Page : 2

Attorney's Docket No.: 09011-002002

REMARKS

Attached is a marked-up version of the changes being made by the current amendment.


Applicant asks claims 1-11, 22 and 28 be allowed. Please apply any other charges or credits to Deposit Account No. 06-1050.

Respectfully submitted,

Date: _____

June 4, 2001

for



John W. Freeman, Esq.
Reg. No. 29,066

Lee Crews, Reg. No. 43,567

Fish & Richardson P.C.
225 Franklin Street
Boston, MA 02110-2804
Telephone: (617) 542-5070
Facsimile: (617) 542-8906

20270705.doc

20270705.doc

Attorney's Docket No.: 09011-002002

In the specification:

This application is a divisional (and claims the benefit of priority under 35 USC 120) of U.S. Application Serial No. 09/054,218, filed April 2, 1998, which claims [benefit] priority from U.S. Provisional Application Serial No. 60/042,678, filed April 2, 1997. The disclosure of the prior application is considered part of (and is incorporated by reference in) the disclosure of this application [hereby incorporated by reference].

Claims 12-21, 23-27, and 29-39 have been cancelled.

22. (Amended) A pharmaceutical composition comprising the polypeptide of claim 1 [or the antibody of claims 18 or 19].